Dr. Bray Links

Saturday, January 28, 2017

Neurocognitive Risk From PCSK9 Inhibitors Hinted in Meta-Analysis

However, when they only looked at the two large studies (ODYSSEY LONG TERM and OSLER), which accounted for about 65% of all patients, they found a more than twofold increase in incidence of neurocognitive events (odds ratio 2.81, 95% CI 1.32–5.99; P=0.007). These events included delirium (including confusion), cognitive and attention disorders and disturbances, dementia and amnestic conditions, disturbances in thinking and perception, and mental-impairment disorders.


No comments:

Post a Comment

Note: Only a member of this blog may post a comment.